News &amp; Updates

People with higher intakes of vitamins C and E in their diet appear to be at lower risk of aortic aneurysm and aortic dissection, as shown in a study.

Dietary vitamins C and E may protect against aortic aneurysm, dissection

Maralixibat may benefit certain subgroups of children with PFIC

Maralixibat may have a role in treating a broader profile of children with PFIC, including those who have had biliary diversion surgery and those with MDR3 deficiency, suggest subgroup analyses from the phase III MARCH/MARCH-ON trials

Maralixibat may benefit certain subgroups of children with PFIC

MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133

Interim results of the Italian, multicentre, open-label, phase IIIb MAURIS trial in “real-world” patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) show similar safety and efficacy to those achieved by atezolizumab plus carboplatin and etoposide in the pivotal, phase I/III IMpower133 trial.

MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133

28 May 2024

High-resolution anorectal manometry detects HD in children ≤2 years old

High-resolution anorectal manometry (HR‐ARM) can be a noninvasive primary screening tool for Hirschsprung’s disease (HD), particularly in children ≤2 years old, as shown in a comprehensive retrospective analysis.

High-resolution anorectal manometry detects HD in children ≤2 years old

CheckMate 648: Nivo + chemo and nivo + ipi continue to improve OS vs chemo in ESCC at 29-month follow-up

After 29 months of minimum follow‐up, nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful overall survival (OS) benefit vs chemotherapy in patients with previously untreated, unresectable, advanced, recurrent, or metastatic oesophageal squamous-cell carcinoma (ESCC), according to results of the global, open-label, phase III CheckMate 648 trial.

CheckMate 648: Nivo + chemo and nivo + ipi continue to improve OS vs chemo in ESCC at 29-month follow-up

Extreme nocturnal heat may trigger stroke events

27 May 2024 by

Exposure to extreme nighttime heat appears to raise the risk of stroke events especially for older adults, women, and individuals with a history of minor strokes, according to a study.

Extreme nocturnal heat may trigger stroke events

Impaired thyroid hormone sensitivity ups MACE risk in angiography patients

Euthyroid patients undergoing coronary angiography who have impaired sensitivity to thyroid hormone are at increased risks of major adverse cardiovascular events (MACE) and cardiovascular death, a recent study has shown.

Impaired thyroid hormone sensitivity ups MACE risk in angiography patients

27 May 2024

A busy brain at work has its cognitive merits later in life

27 May 2024 by

Individuals who held cognitively demanding jobs between the ages of 30 and 60 had a lower risk of mild cognitive impairment (MCI) and dementia after 70 years, findings from the HUNT4 70+ study suggest.

A busy brain at work has its cognitive merits later in life

No link between ultra-processed food consumption and cardiovascular events risk

Eating ultra-processed food products does not appear to contribute to a significant increase in the risk of cardiovascular events, according to a study.

No link between ultra-processed food consumption and cardiovascular events risk

Original New Drug Application Approvals by US FDA (1-15 May 2024)

New drug applications approved by US FDA as of 1-15 May 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2024)